Annual campaign increases education about/awareness of hazardous drug exposure through complimentary CE programs and safe handling initiatives. - February 04, 2010 - Carmel Pharma., Inc.

GenScript draws attention from UPENN School of Medicine for obtaining best quality products and services. - January 28, 2010 - GenScript USA Inc.

GenScript plans to expand its Japanese market from its capital. - January 21, 2010 - GenScript USA Inc.

GenScript’s click peptide service aims to handle difficult peptide you intended to study. - January 21, 2010 - GenScript USA Inc.

Smartly-designed components are even easier to use, offer reliable PhaSeal® protection. - January 20, 2010 - Carmel Pharma., Inc.

Offerings Include Personalized Cost Savings Demonstrations, Blue Man Group Ticket Giveaways and More - November 22, 2009 - Carmel Pharma., Inc.

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs - November 01, 2009 - Carmel Pharma., Inc.

Electronic cigarettes have been gaining much attention in the press. On http://www.electroniccigarettesreviews.net, readers receive the most accurate information on trends in this industry, as well as user reviews of various e-cigarette brands. - October 23, 2009 - ElectronicCigarettesReviews.net

Offerings to include Live pH Test demonstrations, Wii giveaway and more. - October 15, 2009 - Carmel Pharma., Inc.

GenScript expands its drug discovery services to assay development. - September 12, 2009 - GenScript USA Inc.

GenScript’s antibody sequencing service aims to accelerate antibody drug discovery and patent applications. - September 05, 2009 - GenScript USA Inc.

GenScript celebrates its 5th anniversary for its peptide services by giving customers 20% off for standard peptide synthesis and modifications. - August 23, 2009 - GenScript USA Inc.

GenScript adds THE™ Anti-DYKDDDDK mAb to the THE™ antibody series. - August 18, 2009 - GenScript USA Inc.

GenScript upgrades its plasmid production platform to enable wider scope downstream applications. - August 07, 2009 - GenScript USA Inc.

GenScript Inc. received $15M investment led by Kleiner Perkins Caufield & Byers (KPCB) to expand its biology and bio-reagent services in drug discovery and development. - June 26, 2009 - GenScript USA Inc.

Nanomi, a leading provider of microsphere-based drug delivery technologies to the pharmaceutical industry, announced today that it joined a consortium for the development of a therapy to prevent chronic kidney disease. In an aging population, the worldwide incidence of chronic kidney disease, requiring... - June 25, 2009 - Nanomi

GenScript offers high quality bundled bio-reagent samples to appreciate customers and assist in biology research under current tough economic condition. - May 10, 2009 - GenScript USA Inc.

Internationally recognized biology contract research organization GenScript Corporation announces its special partnership promotion for gene synthesis service, which aims to establish a long-term, high-volume, and preferred vendor contract with its partners by offering them specially discounted service... - April 22, 2009 - GenScript USA Inc.

Offerings Include Interactive Product Efficacy Demos, Opportunities to Speak with PhaSeal Developers, Complimentary Starbucks Cards and More. - April 17, 2009 - Carmel Pharma., Inc.

National Campaign Aims to Protect Healthcare Workers from Hazardous Drug Exposure. - February 26, 2009 - Carmel Pharma., Inc.

Healthcare professionals are invited to participate in a free, one-hour safe handling CE webinar addressing the proper handling of hazardous drugs on April 20, 2009, the inaugural Safe Handling Awareness Day. - February 24, 2009 - Carmel Pharma., Inc.

Offerings Include Live Leakproof Integrity Test w/ Industry Thought Leaders, New Product Demos, Nintendo Wii Raffle and More. - December 05, 2008 - Carmel Pharma., Inc.

Due to decreased reimbursements from managed care companies, Hickory Family Practice in Hickory, N.C., began looking for different avenues to increase profitability. Integrating physician medication dispensing through Physicians Total Care allowed Hickory Family Practice to generate additional revenue for the practice. - May 27, 2008 - Physicians Total Care

Carmel Pharma, Inc. will introduce the new Injector N35 with ErgoMotion™ at the 33rd ONS Annual Congress in Philadelphia, PA. This new component employs the innovative and unique technology of ErgoMotion™ - a simple turn-key motion that provides easy access during hazardous drug preparation... - May 16, 2008 - Carmel Pharma., Inc.

Avanti Therapeutics, a privately held biopharmaceutical company, said it has incubated and launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee Therapeutics hopes to commercialize nanomedicines using its proprietary, cell specific targeted drug delivery... - March 28, 2008 - Chikujee Therapeutics

Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals

Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan Pharmaceuticals... - January 09, 2008 - Samaritan Pharmaceuticals

The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health is... - January 03, 2008 - Samaritan Pharmaceuticals

Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals

Scientists recently released the results of the first ever national survey which assessed nurses’ extent and frequency of exposures to common health care hazards. - December 19, 2007 - Carmel Pharma., Inc.

Cardiovascular Sciences, Inc. (CVSC), a corporation under the laws of Nevada, is excited to reveal an initial funding event with Seven Palm Investments, LLC of Illinois. After a recent assessment and restructuring of the company’s equity, the company and its investors are ready to move ahead in... - December 12, 2007 - Cardiovascular Sciences, Inc.

Today, Carmel Pharma, Inc. introduces the Injector Luer Lock N35 with ErgoMotion™ during the 42nd ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV. - December 03, 2007 - Carmel Pharma., Inc.

In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals

Carmel Pharma, manufacturer and distributor of PhaSeal, announced that they are sponsoring a live, accredited continuing education (CE) seminar during this year’s 42nd Annual ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV in December. - November 09, 2007 - Carmel Pharma., Inc.

Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

Aerotrim (Warminster) Ltd has secured a £3.9M order for manufacturing insulation lining for MoD tentage used in field operations. - August 04, 2007 - Aerotrim Group

New evidence-based research was presented at ONS Congress by MD Anderson and the University of Utah which concluded only the PhaSeal System confined the drug, thus proving the prevention of drug exposure from preparation through administration of hazardous drugs. - May 05, 2007 - Carmel Pharma., Inc.

Carmel Pharma, Inc. launches their new Protector 28 (P28). This preparation component is the latest advancement of the PhaSeal System and is available now. - May 03, 2007 - Carmel Pharma., Inc.

Carmel Pharma, manufacturers and distributors of PhaSeal, announced today that they are now offering an accredited continuing education (CE) program developed by STAT Educational Services, an accredited provider of continuing education for various healthcare professionals. - April 25, 2007 - Carmel Pharma., Inc.

New evidence-based research for determining adherence to the NIOSH definition of a closed-system will be unveiled during ‘Ask the Experts’ at the ONS Congress on Wednesday, April 25 in Las Vegas, NV. ‘Ask the Experts’ will be held from 1pm-2pm on Wednesday, April 25 in the Carmel... - April 04, 2007 - Carmel Pharma., Inc.

Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in the... - August 15, 2006 - Blue Sky Biotech, Inc.

Blue Sky Biotech, Inc. announced the Feb 1st appointment of Norman Garceau, Ph.D., as Chief Scientific Officer. Dr. Garceau previously worked in early drug discovery at the Pfizer Research Technology Center (Cambridge, MA) from 1999 to 2006, engaged in a range of activities that included gene cloning and expression profiling, cell biology, assay development, and lead discovery. - March 15, 2006 - Blue Sky Biotech, Inc.

Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying, an advanced particle design technology. Building on its accumulated expertise in all major areas of API development and cGMP manufacture, a full range of cGMP Spray Drying facilities operating at lab, pilot and industrial scale have now been installed at Hovione's API manufacturing plant in Europe and are currently being installed at Hovione’s Technology Transfer Centre in New Jersey, USA. - August 26, 2005 - Hovione